Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
1.090
-0.080 (-6.84%)
At close: Jul 2, 2024, 4:00 PM
1.120
+0.030 (2.75%)
After-hours: Jul 2, 2024, 6:14 PM EDT
Immuneering Stock Forecast
IMRX's stock price has decreased by -88.8% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Immuneering stock have an average target of 15.14, with a low estimate of 3.00 and a high estimate of 25. The average target predicts an increase of 1,288.99% from the current stock price of 1.09.
Analyst Consensus: Buy
* Price targets were last updated on May 8, 2024.
Analyst Ratings
The average analyst rating for Immuneering stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 4 | 3 | 3 |
Buy | 1 | 1 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 9 | 10 | 9 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,276.15% | May 8, 2024 |
Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,276.15% | Apr 12, 2024 |
Mizuho | Mizuho | Strong Buy Maintains $20 → $8 | Strong Buy | Maintains | $20 → $8 | +633.94% | Apr 2, 2024 |
Jefferies | Jefferies | Strong Buy → Hold Downgrades $16 → $3 | Strong Buy → Hold | Downgrades | $16 → $3 | +175.23% | Mar 15, 2024 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $21 → $16 | Strong Buy | Maintains | $21 → $16 | +1,367.89% | Mar 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.04
from -1.88
EPS Next Year
-1.76
from -2.04
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 90.1M | 159.8M |
Avg | n/a | n/a | n/a | 25.6M | 57.6M |
Low | n/a | n/a | n/a | n/a | 14.2M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 525.5% |
Avg | - | - | - | - | 125.4% |
Low | - | - | - | - | -44.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.68 | -0.70 | -0.87 | -0.83 | -0.02 |
Avg | -2.04 | -1.76 | -1.95 | -1.70 | -1.36 |
Low | -2.11 | -2.38 | -2.65 | -2.80 | -2.41 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.